

15 December 2016

**FerriScan data from U.S. and China showcased at the
58th American Society of Hematology conference (ASH), San Diego**

Resonance Health (ASX:RHT) gained significant profile at the prestigious ASH conference held 3-6th December with several presentations of studies by independent experts using the Company's FerriScan[®] technology. The studies demonstrate broadening acceptance of FerriScan in iron monitoring and management and included results from the multicentre US TWITCH study and from China's Guangxi Medical University. The TWITCH study data provides further clinical evidence for use of FerriScan for management of patients with sickle cell disease (SCD), adding impetus to the Company's focus on this market and its strategy to obtain expert advice regarding a renewed CPT code application in the USA.

The ASH conference is the world's premier event in malignant and non-malignant hematology attended by over 20,000 delegates worldwide with almost 250 exhibitors. Resonance Health achieved a strong presence with a booth featuring new corporate videos attracting many new enquiries from delegates.

An oral presentation by Dr Banu Aygun from the Cohen Children's Medical Center, New York, showed how FerriScan can be used to monitor iron unloading by therapeutic phlebotomy in previously transfused children with sickle cell anemia. The results were obtained during the multicentre TWITCH study in the USA.

New FerriScan data from clinicians at Guangxi Medical University, China, was also presented at the lively ASH Poster session by Dr Rong rong Liu demonstrating the prevalence and severity of iron burden in non-transfusion-dependant thalassaemia (NTDT) in China as identified by FerriScan in 158 patients. The abstract concluded that the first FerriScan assessment should be performed as early as 5 years old, emphasising the importance of the technology in this patient cohort.

To read the abstracts please [click here](#).

Resonance Health secured many high value meetings with stakeholders during the conference including new and long-standing pharmaceutical industry partners, medical key opinion leaders and patient advocacy groups keen to support greater access to the Company's leading technologies. The team also held an evening symposium to explore further the role of FerriScan and HepaFat-Scan in the management of health of cancer survivors, a new indication emerging for the Company's technologies and a significant new market.

Professor Tim St. Pierre, Chief Scientific Officer for Resonance Health, commented on the success of the conference:

"The ASH conference was an excellent opportunity for us to strategically position Resonance Health to contribute significantly to the ongoing clinical advances in iron monitoring in a variety of diseases and hold some very high value meetings. The conference is a vital platform for us to share our expertise as global leaders in this field with FerriScan remaining the only FDA approved, standardised technology for accurate non-invasive measurement of liver iron concentration.

We continue to work dynamically with all stakeholders to showcase our world leading products, our new technologies and our proven capabilities as an imaging core laboratory at carefully selected events such as ASH. We are delighted with the opportunities we will now be pursuing into 2017 as a result of this very successful conference."

For further information please contact:

Sander Bangma
General Manager, Resonance Health
E: SanderB@resonancehealth.com P: +61 (0)8 9286 5300

About ASH: *The American Society of Hematology (ASH) invited delegates to San Diego, California, for its 58th annual meeting. The ASH Annual Meeting is the world's premier event in malignant and non-malignant hematology. The meeting provides an invaluable educational experience and an opportunity to review thousands of scientific abstracts highlighting updates in the hottest topics in hematology. Providing delegates with the opportunity to network with top minds in the field, as well as a global community of more than 20,000 hematology professionals from every subspecialty.*